Pulmonary Arterial Hypertension

PAH-SYMPACT<sup>®</sup>: A Reliable Instrument for PAH Symptom Assessment

PAH-SYMPACT®: A Reliable Instrument for PAH Symptom Assessment

By

The Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire has good psychometric properties and can be administered in clinical practice.

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

By

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

By

In patients with pulmonary arterial hypertension who were treated with a parenteral prostanoid, survival was linked with the number of guideline-recommended lower-risk and higher-risk criteria attained.

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

By

Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

By

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

By

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

By

In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.

Perioperative Risk Assessment in a Patient With COPD

Perioperative Risk Assessment in a Patient With COPD

By

A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

By

Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

By

Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.

Middle-Aged Woman With Progressive Exertional Dyspnea

Middle-Aged Woman With Progressive Exertional Dyspnea

By

A 57-year-old woman has been experiencing progressive exertional dyspnea during the past 6 months as well as a near syncopal episode while attempting to catch a taxi.

A 32-Year-Old Pregnant Woman Presents With Worsening Dyspnea

A 32-Year-Old Pregnant Woman Presents With Worsening Dyspnea

By

Several months after being diagnosed with pulmonary arterial hypertension, a 32-year-old pregnant woman presents with worsening dyspnea.

PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

By

Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions for US veterans are inconsistent with pulmonary hypertension guidelines.

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

By

Patients with pulmonary arterial hypertension may be better identified through a claims-based algorithm that includes ICD-9-CM codes, specific pulmonary arterial hypertension medications, echocardiography, and right heart catheterization.

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

By

Women with pulmonary arterial hypertension experienced better long-term prognosis than men with PAH.

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

By

Enlargement of the right atrium is associated with an increased risk for supraventricular arrhythmias in PAH.

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

By

Peak circulatory power offers greater value than peak oxygen uptake and ventilation in predicting cardiac events in patients with idiopathic PAH.

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

By

Hypoxemia in individuals with idiopathic PAH is associated with increased mortality risk.

Pulmonary Embolism With Low Mortality Risk May Be Managed in Outpatient Setting

Pulmonary Embolism With Low Mortality Risk May Be Managed in Outpatient Setting

By

Observation in the emergency department followed by outpatient management with anticoagulation may be appropriate treatment for some patients with low-risk pulmonary embolism.

Safety and Validity of Pulmonary Embolism Rule-Out Criteria Evaluated

Safety and Validity of Pulmonary Embolism Rule-Out Criteria Evaluated

By

In patients at very low risk for pulmonary embolism, the pulmonary embolism rule-out criteria was noninferior to the conventional strategy of identifying thromboembolic events.

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

By

The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.

Pulmonary Arterial Hypertension: Improving Survival Rates

Pulmonary Arterial Hypertension: Improving Survival Rates

By

Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.

REVEAL Risk Score for Long-Term Outcomes in PAH

REVEAL Risk Score for Long-Term Outcomes in PAH

By

The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.

PAH: Implantable Treprostinil Delivery System Is Promising

PAH: Implantable Treprostinil Delivery System Is Promising

By

A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

By

A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

By

A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

By

Hemodynamics may improve in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty with complication rates comparable to pulmonary endarterectomy.

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

By

Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

By

Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

By

Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.

Sign Up for Free e-newsletters